Status:
WITHDRAWN
Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer
Lead Sponsor:
Pfizer
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
This study will assess the effectiveness of CP- 751,871 when given in combination with docetaxel to women with the first occurrence of advanced breast cancer disease. The effectiveness will be measure...
Eligibility Criteria
Inclusion
- histologically or cytologically confirmed diagnosis with evidence of either metastatic disease (Stage IV) of locally recurrent disease not amenable to curative resection or radiation therapy (Stage IIIB).
- Her-2negative breast cancer or unknown Her-2 status.
- at least 1 measurable lesion as defined by RECIST.
- ECOG status 0-1
- adequate bone marrow, hepatic and renal function.
- left ventricular ejection fraction of greater than or equal to 50%.
- willingness to discontinue hormonal therapy.
Exclusion
- any previous chemotherapy for advanced disease.
- prior exposure to taxanes as (neo) adjuvant treatment less than 12 months prior to randomization.
- symptomatic brain metastases.
- prior anti-IGF-1R based investigational therapy.
- peripheral neuropathy greater than grade 2.
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00678626
Start Date
April 1 2009
End Date
September 1 2011
Last Update
May 4 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.